Hasil Pencarian - Douangsone D. Vadysirisack

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.

    Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. oleh Miriam L Fichtner, Michelle D Hoarty, Douangsone D Vadysirisack, Bailey Munro-Sheldon, Richard J Nowak, Kevin C O'Connor

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Myasthenia gravis complement activity is independent of autoantibody titer and disease severity

    Myasthenia gravis complement activity is independent of autoantibody titer and disease severity oleh Miriam L. Fichtner, Michelle D. Hoarty, Douangsone D. Vadysirisack, Bailey Munro-Sheldon, Richard J. Nowak, Kevin C. O’Connor

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices

    Human Neutrophils Respond to Complement Activation and Inhibition in Microfluidic Devices oleh Sinan Muldur, Sinan Muldur, Douangsone D. Vadysirisack, Sharan Ragunathan, Yalan Tang, Alonso Ricardo, Camil Elie Sayegh, Daniel Irimia, Daniel Irimia

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

    Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation oleh Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, Michelle D. Hoarty, Rohit Vyasamneni, Douangsone D. Vadysirisack, Zhong Ma, Nanqun Zhu, Jian-Guo Wang, Charlie Bu, Bestine Cong, Elizabeth Palmer, Petra W. Duda, Camil Sayegh, Alonso Ricardo

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

    Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation oleh Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, Michelle D. Hoarty, Rohit Vyasamneni, Douangsone D. Vadysirisack, Zhong Ma, Nanqun Zhu, Jian-Guo Wang, Charlie Bu, Bestine Cong, Elizabeth Palmer, Petra W. Duda, Camil Sayegh, Alonso Ricardo

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria

    Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria oleh Austin G. Kulasekararaj, Anna-Elina Lehtinen, Cecily Forsyth, Shreyans Gandhi, Morag Griffin, Sixten Körper, Gabor Mikala, Petra Muus, Ulrik Overgaard, Christopher J. Patriquin, Humphrey Pullon, Yu-Min Shen, Ruth Spearing, Jeff Szer, Guillemette de la Borderie, Petra W. Duda, Ramin Farzaneh-Far, Sharan Ragunathan, Camil E. Sayegh, Douangsone D. Vadysirisack, Hubert Schrezenmeier

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: